Overview
- Editors:
-
-
Adam L. Halberstadt
-
Department of Psychiatry, University of California San Diego, La Jolla, USA
-
Franz X. Vollenweider
-
Psychiatric University Hospital, Heffter Research Center Zurich, University of Zurich, Zurich, Switzerland
-
David E. Nichols
-
Division of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, USA
- The volume brings together clinical and preclinical research literatures
- A balanced view of the potential risks and benefits of these compounds is presented
- The focus is on rigorous scientific findings in a field that has been fraught with speculative reports
Access this book
Other ways to access
Table of contents (15 chapters)
-
-
-
- Juan F. López-Giménez, Javier González-Maeso
Pages 45-73
-
- L. Lladó-Pelfort, P. Celada, M. S. Riga, E. Troyano-Rodríguez, N. Santana, F. Artigas
Pages 75-105
-
-
- David A. Martin, Charles D. Nichols
Pages 137-158
-
- Adam L. Halberstadt, Mark A. Geyer
Pages 159-199
-
-
- Katrin H. Preller, Franz X. Vollenweider
Pages 221-256
-
- Michael Kometer, Franz X. Vollenweider
Pages 257-282
-
- Dennis McKenna, Jordi Riba
Pages 283-311
-
- Leo Hermle, Rainer Kraehenmann
Pages 313-332
-
- John H. Halpern, Arturo G. Lerner, Torsten Passie
Pages 333-360
-
- Michael P. Bogenschutz, Stephen Ross
Pages 361-391
-
- Frederick S. Barrett, Roland R. Griffiths
Pages 393-430
-
- Katrin H. Preller, Franz X. Vollenweider
Pages 1-1
About this book
This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.
Reviews
“This book brings together the latest basic and clinical research into the underlying mechanism of action, effects, and possible clinical uses of psychedelic drugs. … It brings together current knowledge regarding this class of drugs pharmacology, neurobiological effects, subjective experience, and therapeutic effects. … It brings together preclinical and clinical data, which will be of interest to anyone involved with or curious about this category of drugs.” (Michael Easton, Doody's Book Reviews, September, 2018)
Editors and Affiliations
-
Department of Psychiatry, University of California San Diego, La Jolla, USA
Adam L. Halberstadt
-
Psychiatric University Hospital, Heffter Research Center Zurich, University of Zurich, Zurich, Switzerland
Franz X. Vollenweider
-
Division of Chemical Biology and Medicinal Chemistry, University of North Carolina, Chapel Hill, USA
David E. Nichols
